期刊
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
卷 44, 期 3, 页码 228-230出版社
INFORMA HEALTHCARE
DOI: 10.3109/00365548.2011.616224
关键词
refractory colitis; tigecycline; Clostridium difficile resistance; abdominal infections; rifaximin
Clostridium difficile colitis infection is on the rise and is considerably increasing the duration of hospital stay, as well as healthcare costs. The management of C. difficile colitis has become more challenging with the increasing failure of therapeutic response to metronidazole and oral vancomycin. Tigecycline is a new glycylcycline that has shown in vitro activity against C. difficile. We report herein a case of C. difficile colitis that failed to improve on a combination of metronidazole and oral vancomycin. The patient subsequently developed a surgical abdomen secondary to refractory C. difficile colitis, but was successfully treated with a combination of rifaximin and tigecycline after she refused to undergo surgical treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据